PKI - Earnings call transcript Q1 2018

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good day ladies and gentlemen, and welcome to the PerkinElmer Q1 2018 Earnings Conference Call. At this time, all participants are in a listen-only mode. Later we’ll conduct the question-and-answer session and instructions will follow at that time. [Operator Instructions] I would now like to introduce your host for today's conference Tommy Thomas, Vice President of Investor Relations. Sir, you may begin.

Tommy Thomas

Sara. you, Thank welcome conference and PerkinElmer quarter first Good to earnings call. XXXX afternoon the in Rob President With Chief call the me are and Officer. Wilson, Financial Executive Friel, Andy Senior Chief Vice and Officer, and Chairman

May If our you of press website XXXX. Investors you live XXth, release, is at the will a website www.perkinelmer.com. get archived from that of and our being this one call earnings may section not have received until copy our on Please be note webcast

made Before that in even everyone earlier statement press SEC change. we forward those to to the of views represent remind update issued our of also if statements any begin, filings. statements only the we we need in our obligation in Any Safe Harbor our looking this release our said forward estimates future afternoon and today outlined today. looking have as We earnings disclaim

not representing forward rely today's on of as So after date views you any our should today. any as statements looking of

this referring attachment measure A will directly plan I'm to of Executive non-GAAP GAAP pleased non most the use GAAP as To non Chief available to during promptly. Friel. extent we’ll to certain measures release. be and reconciled press earnings call measures Rob introduce Chairman to financial the to Officer we we financial now are attachment Rob? of this the reconciliations measures. provide not use this reconciliation comparable financial the to that during GAAP call GAAP PerkinElmer that our is an During call, we in

Rob Friel

over to our delivering and of pleased slightly attributable beat] to and $X.XX, from and QX organic for mid-point share our organic the you very X% excellent [EPS growth thank progress higher XX% growth. lower Adjusted X% for of per than the earnings the us in representing planned. of of the report good growth organic and first rate base earnings. growth growth and was representing than the Revenue tax was I'm $X.XX business comprised a revenue afternoon better quarter to $XXX reported incremental XX% today. was Good Tommy. growth Thanks, of growth last in PerkinElmer The X% revenue had and quarter XXXX from EUROIMMUN's million, start guidance. joining year

each addition financial In in to to aligned invest and our shifting two opportunities made best are growth capabilities while the those on areas, impressive notable our performance, progress with businesses of portfolio our high towards that expertise. our objective

ahead which our moving feel and full to Given profit raising a you few revenue our expectations, and confident in minutes. results year we guidance, positive I'll speak in

organically end represents Sciences, mid-teens academic mid-singles growing now of which to and revenue The X%. biotech, markets, single in Diagnostics, digits growing our but organically. were grew pharma, EUROIMMUN with environmental on the organically, our our by includes reported our and Life largest mid-single of high increased food customers and a and on increased basis core a environmental softness organically digits and food our organically and grew revenue Diagnostics industrial mid-single industrial, end organically. XX% of business government biotech to about and Sales customers, and basis reported grew represents on markets. a XX% organically basis Turning market sales X.X% and revenue XX% which of X% and XX% and to markets X% and includes reported customers and offset Within Sales some remaining sales is and revenue increased organically. applied the pharma academic in our XX% government

positions high and conditions, single favorable Science a as as market respective two growing end our Diagnostics excellent Life largest We our market well execution. combination strong are very pleased through to digits see markets of and

with pleased profitability. our breadth being also initiatives the this to increase very progress So the our in on I growth of excited to am with quarter, addition

quarter anticipated, supplier margins on consolidation the as and operating we collaboration. very costs and contracted we've low made through in good product sourcing While progress cost reducing both

track next deliver we addition processes manufacturing in and on million over through XX lean are years deployment in costs two footprint our savings to In of optimization. the the

we’re single with go to first regulatory growth one result the continue confident The integration and by of the on labs. of of ELISA U.S. the commercial as to make resources a our wins, is As I digit key of to of new operating very expect operating reference some to margins as during this automated outlined good we initiatives organic basis in that yielding by achieve we will of placing the combination year, the very the year well. XXXX. In continues achieve goal Also XXXX. XX earlier well points for XX% remain XX nice quarter, workstations already the evidenced by recently we margins as growth we number our progress in able high year EUROIMMUN large the improvement

I across of in on we globally prioritize between these EUROIMMUN, improve third resources reproductive to an consumers. combined received service new will new to genomics the portion greater many on while In reduce FDA you with diagnostics and all business, health as synergies look of our improve our gross this commercial the identifying opportunities to transitioned assays business, continue U additional to detection two which We’ve of calls. lupus are And time forward integration XX S addition, engineers, and we the of test, Diagnostic we EUROIMMUN, also response approval applied costs and year. submit regulatory later tool technology to equipment portfolio additional updating assays parties business China to for and India. groups EUROIMMUN continue our now PKI from immuno expect

ability the We trisomy future research in apply to in Reports look shipments prenatal One the non-invasive of in A recently demonstrating to maternal clinical diagnostics Marking in assay solution. growth first proof-of-concept receiving plasma. of with data shortly the in detail forward our published CE for Nature is XX second key to testing commencing drivers half. study Vanadis Vanadis Scientific the detection

service is XXXX the first Diagnostic reach the whole of $XX genome perform with other business the of from processed sequencing third we selected just genome XXXX million In sequencing its area in as at some Dystrophy field about rare samples million PerkinElmer the our using to revenue of track new [Duchenne recent gene] To that well announced attractive margins. Genomics. as in research, Project our assay. disease in for mention $X The partnerships of on entire exciting together inroads quarter, new we ramping testing a to PerkinElmer genomics comprehensive populations. remain Muscular genetic and focus couple organizations leading as The genomics the highlights, make of Parent as the healthy a full partner to areas of

the initial are with XX that We collaborating also with Helix, Medical being Genomics reducing gene interventions significantly College and clinical aimed first conditions Genetics with panel mortality. morbidity at the established product one genetic identifies and products the of also of American the as

and to Solutions Turning our Analytical Discovery or DAS business.

business January, accelerating place organization As in in I in growth cohesive as the to discussed single operate priorities more and processes] both shifting from [pre-new consistent. to being are business a the of

customers of and distributed pharmaceutical service manage leverage are components productivity. key for systems discussing data our ensure strategy improve our to OneSource continue offerings is and them informatics us of connected where that avoid informatics lab research, to capabilities. silos, a the the unique with data A requirements of complex is model lab customer’s to our sets, OneSource driving service a and linked One compliance to to number

last made we investments year to growth the of fuel this year. Some are starting

our new uptake to launched our at global our research, experienced review the for functionality, the which clinical we in-house of translational, program. and Signals example, version has has its For end to biologics, last pharma power launched led analytics new development enterprise [Kendro] PerkinElmer search, we platform one and year with clinical in of which analytics the top trial including significantly selecting market. customers of good increased Also Application

better ultimately believe scientists can by scientific connectivity Going to is our customer with used base. increase XX,XXX we forward, offering, Kendro leveraged the be which revenue and

address growth continued in DAS our markets by increased manufacturing markets to quarter, strategy capabilities. the and in China localization is first that DAS Another accelerate emerging to needs. the of investments important capabilities expanding unmet growth organization component with local improving build the emerging In

expect our elemental expand producing now in close product are three to in products. lines and to on soon a China We analysis and small China acquisition

For life across business, first in China the sciences and high-teens growth the DAS broad grew quarter base market. applied with

help Finally develop will businesses solve their to our new to challenges. and customers pressing most products both support innovative continue

We are introduced and from EUROIMMUN, through new of in targeting million first generated again incremental products, from we products year. exclusive revenue $XX the of quarter last $XX the million

to summarize a quarter, the to off So great are start. we

is organization for markets our this financial be deliver continue ability forecast we end executing good and our part The the about feel to year. most well robust. on to for Our

However, progress financial quarter we more EPS progress both our recognition our that profitability achieve opportunities available increased year. the the in company first to strategic for we and and XXXX. have In adjusted should us, both accelerate the of have and continuing the the importantly, to the made and we both the guidance on outlined of growth profile good very continued make priorities revenue for

guidance. as our growth While $X.X to exchange we well since our base discuss in for reflecting organic our Andy will changes foreign revenue slightly both are forecast EUROIMMUN, increasing prior stronger and the rates details, year billion, the as in business

also EPS $X.XX guidance represents our over adjusted is of above XXXX. increasing to are XX% an previous which We increase our and guidance $X.XX,

I'd that to the Andy financial be oversight the over role like PerkinElmer's played only over his call and our I last Before leadership not turn of to last has but a the everyone of moment for he Andy's in PerkinElmer the remind this also years. function, nine I to to will earnings thank would transformation significant call. for take like Andy,

the our to employees senior tenure, a During him On PerkinElmer's Andy and company. wish of gratitude the ensure transition. able increased portfolio, express his Andy's to sincere the strengthen significantly team Andy's leadership well. profile, and behalf of the to and PerkinElmer, for all our appreciate also of evolve were we leadership entire financial like smooth I value I'd to commitment

Financial Jamey Officer, new Mock's be Our day first will tomorrow. Chief

However, joined like evening. Andy. now to us to call this I'll the has he turn over

Andy Wilson

and PerkinElmer. I'd XX% especially where afternoon, to additional first the my express increased as my some future. for inspirational We time quarter appreciation and start Jamey quarter XXXX, kind with on result second the expectations move per Thanks financial over XXXX, the for also success earnings like as guidance you to our last I'll X%. set on reported new good year, with the details in in January. well served our throughout results market, organic revenue quarter first Rob. back I'll want to the million share of full all on me at XXXX Adjusted adjusted exceeding Mock approximately I summary helped first to the to And increased have people now the color wish XX% quarter, who our pleased our for quarter for first everyone. and the of words, many as our year. around CFO; growth $XXX the the provide grew continued were in end of to revenues

sciences approximately Foreign adding By Analytical Solutions life of EUROIMMUN. sales acquisitions end of exchange first approximately organic XX% our revenue approximately a in informatics organic in sales representing approximately specifically total XX% represented revenue OneSource highlighted driven total segment, the from by tailwind strength for with of X.X% by approximately first and business offering. diagnostics quarter the grew X% Discovery markets, growth and in approximately solid XX%. quarter organically the X% growth and representing

strength all with build We us momentum backlog Europe. in entering are solid and see regions a geographies. I'll demand in experienced additional teen’s revenue and organic quarter very India result high revenue BRIC in we digit provide as continued growth single single Brazil, and Asia, continued This additional of businesses major In a pleased growth were order in by geographies we organic growth mid three moment. growth color experienced across healthy the both Americas on giving all quarter. in performance in mid teen’s driven high organic growth strong represents quarters in second the digit to We revenue growth a able the revenue across in the to China. consecutive some major organic

results. of Moving to details operating our the

FX of quarter of year with productivity were First year from reported XX.X%, XX approximately XX.X% of Vanadis X.X% expenditures and Reported by and on continued results from points driven development prior by the was and basis gross the basis an revenue, points our offset basis SG&A inclusion the impacted addition up unfavorable favorably the a approximately impact basis on of Adjusted prior EUROIMMUN XX up driver basis initiatives, increase. the up EUROIMMUN. and margins dilutive being partially XXX basis. mix adjusted benefits were points the up neutral exchange. primary from by foreign points of adjusted in XX the and Research investments EUROIMMUN were

adjusted operating consistent profitability. recently approximately basis, - net impact wanted flow our through on mostly and significantly XXX dynamic. revenue basis adjusted quarter our EPS. expenses. yuan points Chinese points years. guidance costs and our denominated exchange have an is to that the revenue increase on in other in teens an and issued reported the from an XXXX a impact as restated cost Xst, was a of our seasonality exchange approximately Please we down note XX result, The this FX our basis margin with with income. EUROIMMUN margin changes is operating - of operating through $X greater increase prior to a offsetting in January standards operating to relative in per basis. pension XX.X% As million impact prior flow forecasted earnings and and accounting for versus plan based describe Because acquisition due structure I was adopted changes mid on changes There global On margin adjusted euro operating of having EUROIMMUN operating our Prior our of neutral to resulted the foreign a distribution foreign down guidance rates, no production in EUROIMMUN's to costs is briefly

discussed euro. have Chinese of in China in XX% and As revenue in Europe we roughly is approximately split and EUROIMMUN's is XX% and XX% yuan

and euros. most expenses are of in R&D of XX% in production However, Germany their as are EUROIMMUN's over expenses

expenses exposed overall the value euro, in slightly through euro result, the of exceeds on roughly as the now value relative in euro in Chinese operating profit. an of As more this Also profit. flow XX% rate the euro results revenue, will the slight to reduction changes euro affects because margin a a to in change PerkinElmer's revenue. through movements now flow the relative dollar operating our increases impact the Consequently yuan in yuan, at our to now in are euro the our the increase but we Chinese on

P&L revenue, headwind quarter, the slight foreign significantly the against more appreciated exchange yuan. the we as much movements first euro the in Given dollar than more experienced a the Chinese reported but in the

current For or the than on million exchange the full will FX year, $XX the at foreign we of rates impact year. approximately million more our revenue the based estimated $XX on be beginning

additional based than less earnings current this add earnings operating a revenue penny rates. will on However, of

our to in guided the be XX basis to our continue meet dynamic flipside to to strengthens not of remaining the we expansion the quarters dollar margins, euro the versus improvement some of the XXXX. downside. to income adjusted range margin will of operating on course, points our this Of that expect putting is operating over deliver represented revenues strong reducing FX three materially environment margin if pressure impacted Despite the current XX

favorable the midpoint new Turning Treasury exceeded per quarter, adjusted guidance is and to result $X.XX, organic passed originally by by rate our on Department provide a tax of more share first tax earnings primarily rate. we outcome guidance anticipated. lower lower to of we $X.XX tax recently the The in a some to law better range driven the growth than

year. of in was with timing as consistent in strong organically verticals. Diagnostics. first of Switching hope life offset our our detection, Looking as the was generation let's end a Amplification further in remain on which exceeded applied which chance of organic markets, over year OneSource Circle high we attribute revenue article strength the for XX current strong amount double-digit our read grew delivered as year. believe expectations to industrial for innovation, opportunities, Rolling The of Analytical digits. growth that to business, X% by sequencing for growth quarter with by our market in were low Broad growth US. all strong expectations, market accurate in in environmental, first single our states Tulip. Discovery business, sold quarter we partially growth single time Nature start market food China we in revenue Technology sciences reproductive during markets teens. And experienced growth as disease single driven by half increased quarter sales to in comparisons year. the to EUROIMMUN by results on during organic revenue the as a serve last digits help and mid strength sciences the to strong revenue Vanadis was drivers confident Reports strong you've be methods. EUROIMMUN show diagnostics and driven particular slightly exclusively up versus during the in softness Germany Life key emerging all core from business Solutions business, feasibility and we business, in strong screening difficult screening. single Core the gene mid based digit the continues instrument revenue due of and micro customer within Haoyuan quarter focus down genomics high for digits was as in first single orders. in well of health We experienced and and our Geographically content for with of last had trisomy focus. informatics segments finally, future digit expected Scientific applied sales our as which driven China the into the newborn partially the organic business fluidic grew In mid exceed offset A first teens growth QX US the quarter mid expectations of strong both growth strength last the discovery Applied growth the I by high first quarter the our but to our growth - and it disease where and this quarter, the Diagnostics direct across to infectious coming

trisomy's filing to after gathering their for XXXX quarter data all As and continue Vanadis is Rob of mentioned, we three CE part shortly application launch expect second the commercial clinical Mark and as approval.

interest first XX%, net I approximately was and statement, the to million our income and - the $XX which tax down adjusted other was rate referenced adjusted for expense approximately Looking refer quarter previously.

balance to the Turning sheet.

As we $XXX we net and with cash. ratio We the quarter of finished $X.X of million debt the announced debt EBITDA to of approximately quarter with times. billion approximately X.X exited adjusted a

our to Turning performance. cash flow

confident To performance revenue remain as to stronger than We in flow to expected market. continues expected our to up contract Our first Singapore a wrap start full timing commitment levels very supporting are inventory pleased operations cash which organic growth the the increase for operating payment deliver including and million. year first related the higher quarter, was in of of EUROIMMUN, and a year, approximately the initiated cash in temporary quarter continuing capital we in with coupled flow due the new than receivables from higher $XXX China moves better delivered a earn-outs half by outpace production OneSource the as well as our to Tulip, year. solid to with impacted free we period, ability pension from the working first from in

milestones achieved year. Vanadis later our remain all launch to - launch quarter, and track this key on the During timeline to

and quarter. by Our both backlog and in our to healthy end build the core encouraged our markets to in ability focus very we’re areas continue

free to believe of year In all margin on operating we for line flow quarters, to which the for expansion addition, three sight contribute stakeholders. of continue successful remaining our fiscal will and a we generation cash XXXX adjusted good a have key

and our revenue given generating of $XXX and results represents exchange billion, $X.X approximately revenue X% expect which organic mentioned, reported slightly We be guidance. business organic reflects are of foreign now quarter base impact adjusted XXXX the with growth full to we the Rob growth current first As revenue, in approximately the which our in EUROIMMUN the increasing EPS year now million environment. stronger coupled XXXX

year, XX full more exclusive to estimated which exchange foreign than the is of For January. now revenues, at we expect in million EUROIMMUN million be tailwind $XX we

to of growth growth to organic Europe Our organic guidance driven applied X% organic we in diagnostics, digit digit and high the expect mid Americas Asia. DAS Geographically single and continue revenue a revenue revenue sciences life excluding markets. organic in and assumes revenue X% in growth single growth mid by in mix EUROIMMUN with

share We per share full are approximately $X.XX, represents earnings our per adjusted year growth. which earnings taking to XX% adjusted

of XX.X%, remainder quarter Our and new $X.XX guidance $X.XX, guidance which slightly our tax rate year. we versus organic our the approximately incremental anticipate $X.XX of initial out-performance which incorporates year full to the an growth, of first higher the of now XX% adds adds approximately approximately

which quarter foreign forecasting organic For growth XX% we're the revenue X% from represents second reported EUROIMMUN exchange revenues of of of in XXXX, X%. million, business, base XXX and the

terms with In concludes of prepared adjusted of forecasting per This adjusted we’d share $X.XX to we open questions. share to foreign exchange this like Sara, from remarks. at the headwinds. my earnings call time benefit up per earnings minimal are guidance,

Operator

Instructions] Our Peterson, first Thank [Operator comes from JPMorgan. question Tycho you

open. line now is Your

Tycho Peterson

just the best it wish Hi, Andy congrats the thanks. off you kick I transition. guess, on say and and we'll

Andy Wilson

you. Thank

Tycho Peterson

on a be -- for headlines we you from contributions talk business? maybe to of the the ramp from relates should going are the it to EUROIMMUN Siemens As in comment for here. couple about around at quick some Can then assets US buying all And questions the you Europe? assuming what

Rob Friel

ramp in course a be will US continue to all base. but it's small relatively very Tycho, significantly, the of

In teens. where exit right now. What assume facilities. to a situation transition way thinking some just the is, are happened traction. southern But some I think but of we've year. Siemens to before sort it good sort up making discussion, But only any in while to as they've But the just this definitively, fact what founder that, maybe the of XXX think of we Siemens the the [Germany saying at anywhere them future significance, participate which they seeing is way look the who discussion to looking to the some point range way Winfried] take given of I out the is or in space phase past, of this facility might to for high at will in to I support as is in that level US discussions those growth to had a in little need get the if year, XX% EUROIMMUN in continue So in any the the of the think that said historically, ramps now. apparently nothing and it's in engineering is we're by hires the the at with to people XX% XXX you about discussion and invest a a a significant the in growth we’re regard a part had sort of they're in costs. the ways the sort of you know engineers it The those it capability from of continuing With we the to extent has Winfried engineers the EUROIMMUN is would also been to wondering particularly couple as phase years growth. is might to government right and to do in in and sort Stöcker, time German support of

Tycho Peterson

XX% the you think so only portfolio? little in helpful. of But are softness it's the for or know talk the bit a the then Okay. industrial. called I out follow where headed can you for That's DAS just up, part things that maybe you about And business.

Rob Friel

a timing I in is bit of down was would Yes, quarter little weakness and in in like but mean, slightly of and for which chemical the US the particularly market industrial the the bit it’s I I It we is orders. in saw a more think I more - timing instrument the weakness of mean, where us, of sector. in really We the Europe say overall saw attribute pretty and good. saw a Asia. I the growth actually would was sort seems little

Tycho Peterson

you. Thank Okay.

Andy Wilson

Hey, it’s Thanks. attribute believe second something and I being said XXX of for $XXX there, QX Sara and sure million. and my before clarify the But our can call. the XXX. just that want you guidance I last to make topline quarter I call, I to said guidance the I topline want But is to all next confirm for I it

Operator

Our comes Sachs. Patrick from next Donnelly, Goldman question

Your line open. is now

Patrick Donnelly

just of China, guidance Thanks. few think it's above was single, strong into coming double-digits growth on teens' been one quarter Maybe for a guidance Great. of well here. I kind for coming another the there, growth low high year high off a quarters rate

So maybe the macro just there. your update us on been some Obviously has region there thoughts in noise.

about about how What So market good just wondering the again how share relative feeling you're feeling you're and environment? so you're feeling to guidance? the

Rob Friel

the at and be Andy you be mentioned this, are sciences, to think It a look diagnostics, us. broad if based pretty break applied I they for I you mid into it China better. life or market growth When of continues teens. as think was Yes, can double-digit great all markets, it all

continue think, there. opportunities about I we excited So, the be to

be sort a little high we the so I to sort But suspect it. I half rather it and were we probably still double-digits get continue think look than cautious at and year will for only the just cautious again of single, would mid we'll up and back the China teens. think of least I in be maybe say I - out about

very there as to thing other continues say well. EUROIMMUN do is I would The well

teens. quarter in first more in high the were the think I they

demand So we said continue pretty broad like to good I and see based.

Patrick Donnelly

bit repurchase Okay. activity this of had deal. And a quarter, then maybe just recent the of EUROIMMUN little on allocation the share in side, you capital spite

where you landscape and any how are side? the with wondering we coming expect changes just allocation on you capital feeling on I'm leverage So guys should are Jim the going in about

Rob Friel

be change. there think Now will I a don't

add think go I the a see in you I into what we think a to that deal - preference have right us would franchises as large bolt-ons, to I now. with call would said some unlikely still past, I’ve the

to the at continue count try delever a So minimum I in will we'll acquisitions keep we but bolt-on and is preference be little flat. as I think said a it to the share past think our then bit, and

that to a flowed because now probably out. intention So say reduce little stock take right we no up would significantly either we that the to increases I of our the shares But see outstanding. extent option price exercise,

Patrick Donnelly

you. Thank Okay.

Operator

Ross now comes Our ISI Evercore question is next Muken, line from Your open.

Ross Muken

Good and guys, Andy afternoon, congrats.

Andy Wilson

you, Thank Ross.

Ross Muken

math in a expansion. pretty just doesn’t margin obviously after of sequential in cadence, a of at QX QX and terms least And the big our it's step-up imply kind

which one, equated, math guess, that's - my the just I so it seems sort last of guess no the is timing play and math from dynamic comp. you a of and seasons that through it maybe obviously it sequentially we the XQ of maybe then this easy around could unique in steps-up on had that or confirm EUROIMMUN better drop is cadence? year, gets business, piece at I QX that incremental But some weak the So, something is too else

Rob Friel

No.

I you described we it as it out. think have anticipate rolling exactly

quarter quarter effect as the a FX. obviously had and dampening seasonally First well lowest being as EUROIMMUN’s

And do points being the it's progress year end of basis get into the - an I through bit can comp. quarter of it quarter. the it the easier over quarter made we at range will with think EUROIMMUN. as we'll an the XXX be anomaly little see second as would math as we you where ramp Fourth a the in higher

how of you it think are well. all kind we're I thinking things about as So highlighted the

Ross Muken

or confirm quarter million gave and different And organic as EUROIMMUN you bunch kind of of Was That's organics there's in or a M&A pieces growth? because the the without give just also EUROIMMUN. helpful. contribution $XX take the about including or with you could

Rob Friel

Correct.

Ross Muken

Okay.

Rob Friel

in will quarterly our It filing. million. $XX actually be was It

Ross Muken

Got of Diagnostics base And on sort quickly business. the it. just

easier. comp So came off X%, a X% so much year, sequentially last you

probably guess point So the I this the segment? sort view will that of on year be lower is the that of

Rob Friel

That's right.

We’re looking to sort ramp of then and sort quarter at there. up sort it from six of of continues second

Ross Muken

Rob. Andy. Thanks, Thanks,

Operator

Your Our is De next from comes of line Bruin, question Bank now Derik America open.

Derik De Bruin

again, pleasure. once Hey, good luck. been it’s afternoon. And Andy Good

Andy Wilson

Thanks.

Derik De Bruin

Hey.

follow Ross's question. to up Just on

quarter, the about contribution what the it’s not that also [bid] So that number, was? on back the core is one organic diagnostics because pro forma we adding revenue it EUROIMMUN we're X%

Rob Friel

Yes.

Derik De Bruin

Okay.

So X% the is... number

Andy Wilson

And was to in about sort bit the and comp point difficult was mid of that health area. is reproductive Ross's way little we single a the it think

applied business fluidics basically little was degradation up in business which we was and That of we because had prior by some to saw a call disease reproductive difficult India China is infectious single comps year. was and what infectious ad was genomics bit driven and have Our slight in cyclical are a be there involved. But the really the little mid-teens micro instruments disease mid-teens. it is the can just which sort mid tendency

Derik De Bruin

Okay. contribute Great. overall [genomics] milestone questions business just next I will you for what's diagnostics. mean, this on follow-up then guess the Vanadis? do year? think the And two the what I And the

Andy Wilson

for we're I as early think hopefully the next And milestone getting by we've do Marked. So expecting Vanadis before I third of said clearly that quarter, is the end quarter. -- CE know but this

year. the type We half idea back second sort And so would $XX that that expectations call million of able out huge in to business of the in million of $X sort that of and half, don’t range. for it but the have sell the - in be that be

second genetic are Your business, question regard referred longer to the term… with or talking testing to XXXX about was you

Derik De Bruin

brand a since it's business. XXXX, new

Andy Wilson

Yes. XXXX million to of $X we're $XX million. targeting sort

Derik De Bruin

you the get Okay. much. very Great. back I’ll Thank in queue.

Andy Wilson

Thanks.

Operator

from comes Cowen. Schenkel, question next Our Doug

Your line is now open.

Doug Schenkel

I Andy things. of years. on want stage and also I afternoon. moving first want off all next for thank and All welcome Well, to to help over Jamie congratulations onto work right. hard the And his Good the

of I So market questions guess my questions just start. in terms couple to end a

end assumption pronounced geography? year then bookings in in on in the and the And not quarter Following you’ve more whether comment would in any or willing changed up on question, guidance? market commentary be and specific you weakness to segment was end for the earlier market context full your to the industrial growth that

Rob Friel

So was all first about industrial down X%. of

down little sort in a flattish So Americas. and mid was in bit just of it up was was bit, things sort APAC. in of calibrate around little to single the Europe digits a It

chemicals think probably was say a is And or it most mentioned in orders. just it's to we of So growth. I the instrument think mid before, split. the industrial pronounced business. I of geographic for petrochemical was single again think low the year, side I timing probably And I digit probably would that

Doug Schenkel

in contribution in generally about tracking key was and on right potentially the terms it out-performance sounds of then speaking contributor this can - quarter? talk terms helpful. of a is ahead market by to in plan if science of life whether you the Super organic part new Okay. And like the the is end quarter, that of their products so, big your

Rob Friel

Yes.

was of over the said nice the which Well, it the life was biotech and informatics in to of came really side business. see. service having government So all there the It particularly X% you're area. specifically sciences. in pharmaceutical But sort and is in and first up of pharma academic and was that, performance correct

sort - of to pharmaceutical little is word we sure companies regard about get really the of are the they product, was think make it's being it out uniquely nice a are as Kendro, talked that getting digitalization that new to the But to starting traction, meet that to are of some was right some offering. seeing instruments. some somewhat their bit we're of situated was buzz able is the But trying of this the I with we need information new so that it And lab. signals

had to some but that capability, And capability so it’s sort OneSource electronic provide time ability combination the analytics a same the the and of at historically. we’ve notebook having of of

of first some performance And the drove the upside what so really quarter. that in

Doug Schenkel

much EUROIMMUN. things customers those the Okay. new And guess I and in I on you strength I assays, break increasing versus down you utilization? guess function of Could a of the guess new was two existing similar quarter question lastly, the customers how

Rob Friel

I customer. have growth broad-based though No. I into What don't is the can geographically. visibility the you tell was the

North whether So it double-digits. EMEA America, looking also China, was you're or

also say sort would the I pretty of So that was the diseases. broad-based growth across

EUROIMMUN, nice you look look allergy, disease if they at growth. So at at if saw infectious also you you if look

I customers. new existing between the pretty or what broad-based, split was - was but tell said you couldn't it like So I

Doug Schenkel

Okay. Got it. Thank you very much.

Operator

Our next question comes from Steve Beuchaw, Morgan Stanley.

open. Your line now is

Steve Beuchaw

Hi. afternoon. Good

Rob Friel

afternoon. Good

Steve Beuchaw

certainly Andy, the I'll congratulations appreciate to echo really thanks ahead go and and everything.

Rob Friel

Thanks. Sure.

Steve Beuchaw

over to as in the I on the on And impact wondered last models, margin quarter? give given our balance you try could some progresses for of quantification just EUROIMMUN? tune any EBIT up the update the line thinking at maybe year time, of EUROIMMUN more if seasonality the us one the how we that

Andy Wilson

We for my corporation. the the in will Yes. progress impact. basis will XX fourth headwind year, through XX basis ramp the flip we points the to prepared through the largest It That talked remarks, be will it XX was EUROIMMUN quarter around make year. as on points

will say it XX would exit So XX year. negative go from, points to the say let's to I we the basis something XX in as

Steve Beuchaw

you've Thanks. Nature saw take wondered the that I had Rob, could around Vanadis fit? you How be that data preliminary you where the data steps. some conversations, then And in Vanadis than you a the the and are potential to on better They article you. surprising is you we your impacting a weren't particularly do assay, Maybe the would are how if Perfect. thinking more priced couple in conversation hope that were so logical you far even big for. of Communications seen is - how market certainly how

Rob Friel

this think I study. I diagnostic and replace have time success know I to compared to and the a screening, pleased purpose everybody's think you're that nice But a period we to that the - of as of for that the we've product test. see is from soon we'll long out said were standpoint to pricing really of is see So a

to are cost to close want today go and labs is a that into simple workflow, sure, the here we that is to again goal both with the as out as well So biochemical the screening really labs, biochemical make doing so structure a that.

thought of at sure that. is assays. whole our least And So Vanadis make to around the again, theory the sensitivity the that again, current is process stay NGS to similar tuned. But that's

a we that similar, in easier to serious. to have XX% the think and XX% at in to better I just want some but we more from we billion. market, minimum it's With guide, think we But argument, arguments think regard a I sure a think perspective why actually as to as workflow much to of I - of a mean, number it's mean, the if economical. market feel we close I take we said, can the we that's rough $X make

Operator

next Arias, comes Our from Citigroup. Dan question

now line Your is open.

Dan Arias

was to testing Thanks. add color the Good expansion? genetic can and How on would to able that much finding of early the business you that is Rob a afternoon, samples little that doing? be Is the that kind what the benefit I for to just the you're from know is you exact are just business something that. having in due side, that of going you're able leverage thesis working being diagnostics guys. other to of just in hand you? some seeing that you idea

Rob Friel

ramp business, that in attracting that's that's I and number I or companies, the it's when of think we the for And And customers. we're protein we very we the distinctive is been before not biochemical mentioned of pharmaceutical look part we have is group in we think finding attracting bio a I the are think what analysis. attractive that newborn provide becoming marketplace genetic collaborations. that's but and reason show are the say and only the but analysis, But it. what up collaborators to at the would I the only you not

Dan Arias

before this one for Okay. And question then expecting I are go. maybe final I interest Andy it could would you income if what you guess be, just ask just year? you

Andy Wilson

now right about million of interest think, $XX I $XX net looking - just income at north we're million. at

Rob Friel

XX.

Andy Wilson

expense. that was that’s XX, net interest Yes. interest question, Net sorry? income, the

Dan Arias

right. That's

Andy Wilson

be around $XX That's million. to going

Dan Arias

Okay. Thanks.

Operator

question - sorry… next I’m Our

Andy Wilson

other. income Net interest and

Operator

March. comes question Our from next William

is now open. line Your

Unidentified Analyst

Guys, how are you?

Rob Friel

Good.

Unidentified Analyst

a bit to little an of assays take Just about time maybe coming think that a contributor? going driven critical kind base with America goalposts more EUROIMMUN, and becoming the of just opportunity instrument? that small of or for getting it's off a On you to saying mass develop? by are that could some a what some to a approvals about talk Is significant

Rob Friel

Yes.

mean, a part I is of of it. piece it think the I regulatory approvals. that's getting

capability. regulatory as formidable so, think invested have we And in not the that now area significantly EUROIMMUN more a much we an past was I had combined mean, I talked that

already. to XX And think of them I closing, we've we're getting since two the filed, already I FDA. the some excited submissions about out mentioned

a piece of that's big So it.

sales I in your the just US force market within is something. expanding and in or probably EUROIMMUN think other XX of presence it was I piece the think the commercial people

And to - helping little doors, of of recognition mentioned opening out sort their piece all brand was, service instruments the I transitioned getting more PerkinElmer. all open bit so some their them getting other that's of of - sort - And the then now just of a we've there.

to So that's not helpful I of customer. think from the responsiveness only but the standpoint cost,

there the in is the trade helpful I awareness, PKI and I So of EUROIMMUN, presence so is of increasing think, as well. combined number shows of a some just think components,

regulatory, those I think, So are branding, presence, the drivers. main

Unidentified Analyst

$XX on then And that genome to in about can the little talked about $X talk business, whole opportunity bit the maybe the terms You've revenues? collaboration in million million a Great. servicing you with just Helix. of

some of a as is or and and As other more standalone offering that to drive revenues? more maybe services you incremental business that it think that trying to products about about try Thanks. with drive bundling your

Rob Friel

is we we sequencing. opportunity. is a the the in think of of past sort because bundling newborn and have talked about both. done do it's starting reasons screening confirmatory we We’ve very were the comfortable really And that, often for through this one So I test

doing sequencing screening the confirmatory. both the the now us by can and we So do

a bundling sort had we customers see natural - to opportunity not we've I or go of us think whether after. captive business approached we could could a Similarly with was of that of something was was ViaCord, do. sort customers that that number

starting that we get an business opportunity and the So with go was about that ramp we're nicely. we time, of that we working the business. talked et we had understanding after. companies But to working see that there and the incremental go captive of we of the pharmaceutical out And Helixes things cetera. same could business the is the And to sort was with thought before some with started some at world,

I if it year, to look fairly evenly opportunities. of million both So our be at between million those of this revenue $XX you could think split $X

Unidentified Analyst

Thanks.

Operator

from Our Steve next comes Cleveland Willoughby Research. question with

is now open. line Your

Steve Willoughby

regarding provide opportunity? there guess, whether little I you. share for questions wanted Two more evening. driven gains first strength service of on you to Good bit customers a kind more, more Greenfield existing penetrating being by that's pharma your I Hi. comments the color and just informatics. the or regarding

Rob Friel

and renewal I think customers penetrating it come informatics little I in So, bit in from new out new saw as of a products particular customers. nice was area, existing with ChemDraw we mentioned a the and

it's customers that, of particular say wins where informatics we're in we those probably service side, in one the and customers. on So do expand periodically get doing existing But having nice XXXX. it's a the mostly with said ramping little continue bit in with I up both. would we we're what to some

Steve Willoughby

just within business? of one trying timing products, are color Okay. And guess least some orders other or on some about any to the far? related gate on see of two that there's talking just so if doing then backlog and system time I think industrial comments if out follow your more so newer how And to those of you equipment your as your wondering that any to I more there's comment comment I'll at just building times on made the regarding

Rob Friel

is say to industrial. the mid were reference mostly more the the as in backlog slower notably the in also the little we a would of quarter, about in probably timing that I I would was food some say talked markets single.

than the area a genomics down would bit. at in I look of third our diagnostics then business the business year, I say mentioned I sort better was we was think, actually will little bit And think applied that. our be core that that a I

going be double-digit for the high grower. that's think probably single-digit, I year to

some good build and where we first that saw year. we quarter that's think So will through in pretty bookings the the

Steve Willoughby

Thanks very Okay. much.

Rob Friel

Okay.

Operator

from next Our Brandon question Couillard Jefferies. with comes

is line open. Your

Brandon Couillard

Thanks. afternoon. Good

Rob Friel

Good afternoon.

Brandon Couillard

you Quick Andy. for one

CapEx first there timing you're interest and that would've what And some outlook offering, year? recent benefit the Because to the related of the with EUROIMMUN any net we should year? for otherwise for quarter full incremental some that? the secondly terms In think debt in €XXX the not note been million expense paying spike down of I pencil in

Andy Wilson

impact down expense pay by net things is on. is two is the did is interest there it the net that Well, going we but One on FX. offset revolver,

really much savings. wasn't So there

far that was a of is concerned, As timing. capital little as bit

have this We a couple started will big fairly I think that of year, normalize. at we beginning initiatives that

to EUROIMMUN's think hit quarter, we're a get we still of we capital like in so for result guidelines our that feel first the the I to and And still we going can think as XXX. capital some on be within year,

So timing. it's really mainly

Brandon Couillard

Great. Thanks.

Operator

question Our comes Quirk, from next Piper Jaffray. Bill

now open. is line Your

Bill Quirk

everybody. afternoon, Thanks. Great. Good

comments what at cost of in not First moving on European DAS made some you revenue some guys or and of base manufacturing EUROIMMUN, you the China. question just doing with thinking denominated some Have considered all to Andy you're business? unlike euro exposure China about

Rob Friel

Yes, already has working absolutely. EUROIMMUN on been that.

large fairly China finalizing in which our in Tianjian. of is facilities and manufacturing similar process the in China continue to to for And ramp to in products are they So China. up sort of approach make

to euro that ’XX. so approval until But yaun that's that will with And probably some do come Chinese those a to this regulatory revenue from probably probably euro we exactly year sort costs costs, based lot shift of online what of to of see base. because later is but won't we're factory the trying

Bill Quirk

for Rob. Okay. staying moment. in Perfect. secondly a EUROIMMUN just Thanks, and And

get XXXX? growth? from we sense years US just the to out push trying a a think here three or both how of expect franchise metering you R&D assays a trying well over call about think You we just talked here. portfolio bit fairly in even little regulatory about trying states a to of number coming Can help approvals about as So as it should you're the bolus to expand the us spend, in should the a

Rob Friel

little we've last I been hard a there as or is we - think as I three I out possible. XX working in a think so there And filed frankly And initially little you will. demand if we to think the those was mentioned trying quickly months. because to get I some quite bolus pent-up

days. approval, Having determining to because of don't in regulatory have larger but not clearly there So forward. But on know pace, better, be as getting was the amount see. XX market the they in we last that probably steady little difficult hope how we'll going it first the the we'll to wait said at a but a which sort I see dependent to can pace that, sort hit But much saw level a quarter. seems we're FDA type and be you that appreciate it's you just of of the

Bill Quirk

Got you. Thank Okay. it.

Operator

Deutsche question Leonard, next from Bank. Our comes Dan

line is open. Your now

Dan Leonard

update Is Rob thinking XXXX? us expect you. portfolio Thank you your the pruning. anything in for should we around on scope can there

Rob Friel

we'll I continue be don't to I material. think there to is We've a to but it going don't anything $XX could things had they I could that look going within bit will that to could of know But at pruning know I it’s be give significance. talked DAS I number million, be like, you those. some and little don't about - million not be significant. it’s $XX that it If be be it something think

Dan Leonard

year? balance the like the Vanadis, further the then on secondly you you like? Are publication cadence could to of expecting would And what look on what papers Okay. looks waterfall comment and

Rob Friel

little sort next that come XX of but then out think next there difficult works we a that in latter - of the there's sort the year. the the or to is is number would right are see think I in - probably a that two so. in we again is this in to And now days there to expect predict, I hope

Dan Leonard

Okay.

Rob Friel

in the three see or four. of maybe we'll So course XXXX

Dan Leonard

Great. Thank you.

Operator

Jack Okay. comes Meehan, And Barclays. next our question from

open. is now Your line

Mitch Petersen

actually Jack is for on Mitch This afternoon. Thanks. this Petersen

[how on the you're could screening terms is and in On regions? the what newborn business, seeing trying utilization influence then elaborate you EM rates just of tax] birth to

Rob Friel

do but or menus rates. all of So, because we’ll of continue of to the pretty to either not expansion It's newborn because, make we first penetration. well, it's of business say expansion continue birth

look that the right talked in of look you bit. The growth there their may as trending a with challenge a to ‘XX rates a journal point they I have sort were would today targets down, the China we was seen of X.X China now you for if in their has think three, and little suppressed birth say that If US, probably Economist are about recent And sort have the points. in birth here you fact, article rates been in in article down the

that, something newborn than a is screening. obviously, issue that's So bigger just

said aspect now being not been growth - birth the globally, rate is it's of but the driven not in of right other the So I sort it. like by on driven newborn business

Mitch Petersen

talking Helpful. some you potentially add the And portfolio? Thanks. to elaborate then the on of I'm to areas just M&A, could where you like

Rob Friel

is go that for back we've talked growth. reinforce this would here I and of priorities sort strategic about

build out in it's So our look across when that's businesses to at diagnostic to emerging something markets, capabilities obviously we the us. continuing interesting

say think and can is we instrument I genomics think provides applied with sort it's significant area where anything lot I our would industry, that And the our out portfolio. opportunity interested. analytical area I out is services consumable, revenue there opportunity be clearly build we area us. I in a in fact of is where a those that of Food, think spend we built two sort DAS in to think fragmented very nice of area believe capabilities. we area would I attractive would very the the our combined for be spite would something pharma a an fairly the

Mitch Petersen

Thank you.

Operator

our to further That would any question-and-answer to turn Rob concludes for remarks. like I call back the Friel now over session.

Rob Friel

all questions. and appreciate So of thanks I for your all first

we're the value who driving only and for just ahead even about mission, not to the are reinforce around And creating so excited in world team me all our that in but shareholders. let moving employees confident the committed terrific of our opportunities closing greater

a for in great and have So PerkinElmer interest thank your evening. you

Operator

program. conclude This Ladies and today's conference. today's thank in does gentlemen, you for participating

all may a Everyone great You disconnect. have day.

Revvity (RVTY) 30 Apr 182018 Q1 Earnings call transcript